IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis

SHANGHAI and NANJING, CHINA, and SAN JOSE, Calif., April 5, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to

Related Keywords

Wei Wang ,Gansu ,China ,United States ,Nanjing ,Jiangsu ,Shanghai ,Tongji ,Sichuan ,Thailand ,Chinese ,Equecabtagene Autoleucel ,Jinhua Zhang ,Drug Administration ,China National Medical Products Administration ,Lancet Regional Health ,Investigational New Drug ,Release Syndrome ,Cell Associated Neurotoxicity Syndrome ,Myasthenia Gravis Activities ,Daily Living Score ,Quantitative Myasthenia Gravis Score ,Myasthenia Gravis Quality ,Life Score ,Modified Rankin Score ,Tongji Hospital ,Tongji Medical School ,Huazhong University ,New Drug Application ,National Medical Products Administration ,Thailand Business ,